Requirements ≈1.3–1.7 mg/day. For specific uses, higher doses are used, without overdoing it.
Reduces morning sickness; it is a first-line treatment.
View the study (clinical trial) →Lowers blood homocysteine (its clinical impact is another matter).
View the study (meta-analysis) →⏱ 3 min read
Vitamin B6 is a water-soluble B-group vitamin that exists in six chemically related forms (pyridoxine, pyridoxal, pyridoxamine, and their corresponding phosphates), all of which can be converted in the body into the active enzymatic cofactor pyridoxal-5'-phosphate (P5P or PLP); this cofactor is essential for more than 140 distinct enzymatic reactions, including the synthesis of neurotransmitters (serotonin, dopamine, GABA, norepinephrine), amino acid metabolism, heme synthesis, and the regulation of homocysteine, a functional multiplicity that explains its broad clinical profile and the specific risks associated with both its deficiency and its excess.
Unlike most water-soluble vitamins, which have wide therapeutic margins, vitamin B6 has a clinically important peculiarity: chronic excess at high doses (more than 200 milligrams per day sustained for months) can produce reversible but potentially severe peripheral sensory neuropathy, a well-documented toxicity that sets B6 apart from the other vitamins in the group and that justifies regulation of maximum doses in many countries.
The indication with the greatest popular use is premenstrual syndrome: several small trials and a meta-analysis published in the BMJ in 1999 suggest moderate improvements on PMS scales and in premenstrual depression with doses of 50-100 milligrams per day, especially for affective symptoms (irritability, emotional lability, anxiety); the magnitude of the effect is modest and the methodological quality of the studies is heterogeneous, but the favorable tolerability profile at those doses (well below the neurotoxic threshold) makes it a reasonable option as a first-line treatment or as an adjunct.
An indication with solid clinical support is hyperemesis gravidarum and first-trimester nausea: doses of 10-25 milligrams every 6-8 hours, alone or combined with doxylamine (a first-generation antihistamine), significantly reduce the severity of nausea, an indication included in international obstetric guidelines (ACOG) and approved by the FDA in the combined formulation Diclegis; it is one of the few drugs with well-established safety in the first trimester of pregnancy.
In combination with folic acid and vitamin B12, B6 lowers plasma levels of homocysteine, an amino acid whose elevated levels are associated with cardiovascular risk in observational studies; however, the large intervention trials (HOPE-2, VISP, NORVIT) have not shown reductions in cardiovascular events with treatment, which calls into question the clinical usefulness of pharmacologically lowering homocysteine in secondary prevention, one of the best-known disappointments of interventional clinical nutrition.
Because of its central role in the synthesis of monoamines (serotonin, dopamine, norepinephrine), B6 has been studied as an adjunct in depression; the data are inconsistent, with marginal benefits in some small studies and no clear effect in others; the possible usefulness appears to be limited to people with documented subclinical B6 deficiency or with mild depression where an integrated nutritional intervention is being considered.
Nutritional doses are 1.3-2.0 milligrams per day in adults (recommended intake); the therapeutic doses discussed range from 10 to 100 milligrams per day depending on the indication; the established tolerable upper limit is 100 milligrams per day in adults, a prudent figure to avoid neuropathy with chronic use; occasional higher doses are acceptable but should not be sustained for months without medical supervision; the active forms (P5P, pyridoxal-5-phosphate) are physiologically more direct than pyridoxine but have not shown clear clinical superiority and are significantly more expensive.
The most important precaution is neurotoxicity from chronic use of high doses: sustained doses above 200 mg/day for months can produce peripheral sensory neuropathy with paresthesias, ataxia, and loss of proprioceptive sensation, a picture that is reversible on discontinuation but sometimes slowly and not always completely; this toxicity has led several countries to limit the maximum dose in over-the-counter supplements; people with Parkinson's disease should be cautious because high-dose B6 can accelerate peripheral decarboxylation of L-DOPA and reduce its efficacy (this effect is prevented by combining it with carbidopa, a standard practice); in epilepsy, high-dose B6 is used in some specific pyridoxine-responsive syndromes under neurological supervision.
Information, not medical advice. Scientific evidence reflects the quality of the studies.